Caligan Partners’s Eupraxia Pharmaceuticals EPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding EPRX
Caligan Partners's EPRX Position: Q3 2026 in Review
Caligan Partners opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q3 2026: 1,163,010 shares worth $10.6M. The stake represents 0.65% of the portfolio and ranks #22 among its holdings.
70 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.
- Caligan Partners held 1,163,010 shares of Eupraxia Pharmaceuticals worth $10.6M as of Q3 2026.
- Eupraxia Pharmaceuticals was a new Caligan Partners position in Q3 2026.
- Eupraxia Pharmaceuticals made up 0.65% of Caligan Partners's portfolio in Q3 2026, its #22 holding.
- 70 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.
Based on Caligan Partners's 13F filing for Q3 2026, filed 16 Nov 2026.